<h2 dir="ltr"><strong>Hemophilia B</strong></h2>
<p dir="ltr"><a href="https://www.delveinsight.com/report-store/hemophilia-b-market"><strong>Hemophilia B</strong></a> is a rare inherited bleeding disorder caused by insufficient levels of clotting factor IX, resulting in prolonged or spontaneous bleeding episodes and impaired blood coagulation.</p>
<h3 dir="ltr"><strong>Hemophilia B Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of Hemophilia B</li>
<li dir="ltr" role="presentation">Severity-specific Diagnosed Prevalent Cases of Hemophilia B</li>
<li dir="ltr" role="presentation">Age-specific Diagnosed Prevalent Cases of Hemophilia B</li>
<li dir="ltr" role="presentation">Diagnosed Prevalent Cases of Hemophilia B with or without Inhibitors</li>
<li dir="ltr" role="presentation">Treated Patient Pool of Hemophilia B</li>
</ul>
<h2 dir="ltr"><strong>Hemophilia B Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">The total diagnosed prevalent cases of Hemophilia B in the 7MM were estimated at approximately 11.5K in 2025.</li>
<li dir="ltr" role="presentation">In the United States, diagnosed prevalent cases with inhibitors accounted for nearly 5%, while non-inhibitor cases represented approximately 95% of the patient population in 2025.</li>
<li dir="ltr" role="presentation">Severity-specific diagnosed prevalent cases in the United States were categorized as mild (36%), moderate (39%), and severe (25%) in 2025.</li>
<li dir="ltr" role="presentation">Diagnosis of Hemophilia B requires specialized coagulation testing, including factor IX activity testing, coagulation studies, and genetic testing to assess clotting abnormalities and confirm disease severity.</li>
<li dir="ltr" role="presentation">Advancements in diagnostic technologies and increasing awareness regarding inherited bleeding disorders are expected to improve diagnosis rates and treatment access during the forecast period.</li>
</ul>
<h2 dir="ltr"><strong>Hemophilia B Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">The Hemophilia B market size in the 7MM was estimated at approximately USD 3.5 billion in 2025.</li>
<li dir="ltr" role="presentation">In 2025, nearly 57% of the total market share was occupied by the United States.</li>
<li dir="ltr" role="presentation">Among currently available therapies in the United States, recombinant FIX &ndash; Extended Half-Life (EHL) therapies captured the highest market share in 2025.</li>
<li dir="ltr" role="presentation">The Hemophilia B market is expected to grow at a CAGR of 8.4% during the forecast period from 2026 to 2036.</li>
<li dir="ltr" role="presentation">Current treatment strategies primarily rely on replacement therapy using recombinant factor IX products, bypassing agents, and emerging gene therapies aimed at long-term FIX expression and reduced treatment burden.</li>
<li dir="ltr" role="presentation">Recent approvals of therapies such as HEMGENIX and non-factor therapies like HYMPAVZI are transforming the treatment landscape by improving convenience, reducing bleeding risk, and supporting long-term disease management.</li>
</ul>
<h3 dir="ltr"><strong>Hemophilia B Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Advancements in Hemophilia B diagnosis are supporting earlier disease detection and treatment initiation.</li>
<li dir="ltr" role="presentation">Rising opportunities in gene therapy and non-factor therapies are expanding the treatment landscape.</li>
<li dir="ltr" role="presentation">The evolving competitive environment with emerging therapies is accelerating innovation and market growth.</li>
<li dir="ltr" role="presentation">Increasing healthcare spending and improved access to advanced hemophilia care are driving therapy adoption globally.</li>
</ul>
<h3 dir="ltr"><strong>Hemophilia B Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Most currently available therapies require intravenous administration, creating treatment burden and adherence challenges, especially in pediatric populations.</li>
<li dir="ltr" role="presentation">Development of inhibitors against treatment products remains a major limitation and can lead to severe complications, including anaphylactic reactions.</li>
<li dir="ltr" role="presentation">Limited treatment options remain available for severe Hemophilia B patients, creating a substantial unmet need.</li>
<li dir="ltr" role="presentation">High treatment costs and long-term management requirements continue to impact patient accessibility and healthcare expenditure.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Hemophilia B Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">BE-101</li>
<li dir="ltr" role="presentation">SR604</li>
<li dir="ltr" role="presentation">REGV131-LNP1265</li>
<li dir="ltr" role="presentation">AskBio009</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Hemophilia B Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">Sanofi</li>
<li dir="ltr" role="presentation">Novo Nordisk</li>
<li dir="ltr" role="presentation">CSL Behring</li>
<li dir="ltr" role="presentation">uniQure</li>
<li dir="ltr" role="presentation">Be Biopharma</li>
<li dir="ltr" role="presentation">Equilibra Bioscience</li>
<li dir="ltr" role="presentation">Regeneron Pharmaceuticals</li>
<li dir="ltr" role="presentation">Intellia Therapeutics</li>
<li dir="ltr" role="presentation">Takeda</li>
<li dir="ltr" role="presentation">And others</li>
</ul>

Hemophilia B Market

Hemophilia B Degeneration Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape.